Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor
暂无分享,去创建一个
C. Larsson | W. Lui | C. Yeh | Ziqing Chen | Shuijie Li | Juan Yuan | R. Bränström | Wen-Kuan Huang | Hao Shi | H. Cui | Jiwei Gao
[1] S. Sleijfer,et al. Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs , 2019, Cancers.
[2] V. Calvo,et al. Cisplatin resistance involves a metabolic reprogramming through ROS and PGC‐1&agr; in NSCLC which can be overcome by OXPHOS inhibition , 2019, Free radical biology & medicine.
[3] K. Urbańska,et al. Unappreciated Role of LDHA and LDHB to Control Apoptosis and Autophagy in Tumor Cells , 2019, International journal of molecular sciences.
[4] G. Patti,et al. Mitochondrial fusion supports increased oxidative phosphorylation during cell proliferation , 2019, eLife.
[5] C. Larsson,et al. miR‐125a‐5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors , 2018, Experimental cell research.
[6] E. Giannoni,et al. Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. , 2018, Cell metabolism.
[7] C. Antonescu,et al. Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor , 2017, Clinical Cancer Research.
[8] Zhenfeng Zhang,et al. Combined Inhibitions of Glycolysis and AKT/autophagy Can Overcome Resistance to EGFR-targeted Therapy of Lung Cancer , 2017, Journal of Cancer.
[9] D. Chitale,et al. Bioenergetic Adaptations in Chemoresistant Ovarian Cancer Cells , 2017, Scientific Reports.
[10] T. Gibson,et al. Metabolic shifts in residual breast cancer drive tumor recurrence , 2017, The Journal of clinical investigation.
[11] Min Zhang,et al. MICU1 drives glycolysis and chemoresistance in ovarian cancer , 2017, Nature Communications.
[12] Zemin Zhang,et al. Adenylate kinase hCINAP determines self-renewal of colorectal cancer stem cells by facilitating LDHA phosphorylation , 2017, Nature Communications.
[13] Bernhard Kuster,et al. Lapatinib Resistance in Breast Cancer Cells Is Accompanied by Phosphorylation-Mediated Reprogramming of Glycolysis. , 2017, Cancer research.
[14] Hengqiang Zhao,et al. Up‐regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine‐resistant pancreatic cancer cells , 2017, Journal of cellular and molecular medicine.
[15] E. Wherry,et al. Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion. , 2016, Immunity.
[16] C. Frezza,et al. Distinct Metabolic Requirements of Exhausted and Functional Virus-Specific CD8 T Cells in the Same Host , 2016, Cell reports.
[17] G. Mills,et al. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. , 2016, The Journal of clinical investigation.
[18] Y. Jo,et al. Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production , 2016, Leukemia & lymphoma.
[19] G. J. Yoshida. Metabolic reprogramming: the emerging concept and associated therapeutic strategies , 2015, Journal of Experimental & Clinical Cancer Research.
[20] C. Heeschen,et al. MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells. , 2015, Cell metabolism.
[21] E. Ragazzi,et al. Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death , 2015, Oncotarget.
[22] J. Koster,et al. SIRT1/PGC1α-Dependent Increase in Oxidative Phosphorylation Supports Chemotherapy Resistance of Colon Cancer , 2015, Clinical Cancer Research.
[23] John M. Asara,et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function , 2014, Nature.
[24] C. Larsson,et al. microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome , 2014, British Journal of Cancer.
[25] P. Schumacker,et al. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? , 2014, Nature Reviews Cancer.
[26] L. Pusztai,et al. Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential , 2014, Breast Cancer Research.
[27] B. Kalyanaraman,et al. Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation , 2014, British Journal of Cancer.
[28] P. Gimotty,et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. , 2013, Cancer cell.
[29] P. Puigserver,et al. PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. , 2013, Cancer cell.
[30] G. Semenza,et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression , 2010, Proceedings of the National Academy of Sciences.
[31] C. Frei,et al. Nutrition Controls Mitochondrial Biogenesis in the Drosophila Adipose Tissue through Delg and Cyclin D/Cdk4 , 2009, PloS one.
[32] Annick D. Van den Abbeele,et al. The Lessons of GIST—PET and PET/CT: A New Paradigm for Imaging , 2008 .
[33] J. Fletcher,et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] J. Fletcher,et al. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. , 2006, Cancer research.
[35] Shaomeng Wang,et al. In vitro Effects of the BH3 Mimetic, (−)-Gossypol, on Head and Neck Squamous Cell Carcinoma Cells , 2004, Clinical Cancer Research.
[36] John Calvin Reed,et al. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. , 2003, Journal of medicinal chemistry.
[37] J. Fletcher,et al. Molecular Insights into the Histogenesis and Pathogenesis of Gastrointestinal Stromal Tumors , 2000, International journal of surgical pathology.
[38] V. Mootha,et al. Mechanisms Controlling Mitochondrial Biogenesis and Respiration through the Thermogenic Coactivator PGC-1 , 1999, Cell.
[39] M. Abou‐Donia,et al. Metabolic fate of gossypol: the metabolism of [14-C]gossypol in swine. , 1975, Toxicology and applied pharmacology.
[40] B. D. Myers,et al. Effect of gossypol on some oxidative respiratory enzymes. , 1966, Plant physiology.
[41] S. Weinhouse. On respiratory impairment in cancer cells. , 1956, Science.
[42] O. Warburg,et al. THE METABOLISM OF TUMORS IN THE BODY , 1927, The Journal of general physiology.